PUBLIC OFFER OF 13,80,000 EQUITY SHARES OF FACE VALUE OF ` 10.00 EACH OF KWALITY PHARMACEUTICALS LIMITED (“THE COMPANY” OR “KPL”)
FOR CASH AT A PRICE OF ` 45.00 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ` 35.00 PER EQUITY SHARE) (“OFFER PRICE”) AGGREGATING
TO ` 621.00 LAKHS (“THE OFFER”) CONSISTING OF A FRESH ISSUE OF 1,80,000 EQUITY SHARES AGGREGATING TO ` 81.00 LAKHS (THE “FRESH ISSUE”)
AND AN OFFER FOR SALE OF 12,00,000 EQUITY SHARES BY TR METALS PRIVATE LIMITED (“SELLING SHAREHOLDER”) AGGREGATING TO ` 540.00 LAKHS (“OFFER FOR SALE”) AND TOGETHER WITH THE FRESH ISSUE (“THE OFFER”) OF WHICH, 72,000 EQUITY SHARES AGGREGATING TO ` 32.40 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER (“MARKET MAKER RESERVATION PORTION”). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION I.E. OFFER OF 13,08,000 EQUITY SHARES OF FACE VALUE OF ` 10.00 EACH AT AN OFFER PRICE OF ` 45.00 PER EQUITY SHARE AGGREGATING TO ` 588.60 LAKHS IS HEREINAFTER REFERRED TO AS THE “NET OFFER”. THE OFFER AND THE NET OFFER WILL CONSTITUTE 26.60% AND 25.21%, RESPECTIVELY OF THE POST OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, PLEASE REFER TO SECTION TITLED "TERMS OF THE OFFER " ON PAGE 253 OF THIS DRAFT PROSPECTUS. THIS OFFER IS BEING MADE IN TERMS OF CHAPTER XB OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009 (THE “SEBI (ICDR) REGULATIONS”), AS AMENDED. THIS OFFER IS A FIXED PRICE OFFER AND ALLOCATION IN THE NET OFFER TO THE PUBLIC WILL BE MADE IN TERMS OF REGULATION 43(4) OF THE SEBI (ICDR) REGULATIONS, AS AMENDED. FOR FURTHER DETAILS, PLEASE REFER TO SECTION TITLED "OFFER PROCEDURE" ON PAGE 259 OF THIS DRAFT PROSPECTUS. All potential investors i.e. Qualified Institutional Buyers, Non-Institutional Investors and Retail Investors shall participate in the Offer through an Application Supported by Blocked Amount (“ASBA”) process providing details about the bank account which will be blocked by the Self Certified Syndicate Banks (“SCSBs”) for the same. For more details please refer chapter titled “Offer Procedure” beginning on page 259 of this Draft Prospectus.
 
       
   

 

   
       © 2008 Kwality Pharmaceuticals Ltd. All Rights Reserved.